Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited (ASX: MYX) is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million.

The transaction could lift its illustrative cash and marketable securities position to $122.8 million while removing a manufacturing-intensive business. However, with quarterly underlying earnings falling 52%, the bigger question is whether Mayne Pharma can convert growing US prescription volumes into sustainable profitability.

Key Numbers Behind the $55.5 Million Deal

• $55.5 million: Cash consideration for Mayne Pharma International, subject to working capital adjustments.
• $70.7 million: International segment revenue in FY26, representing approximately 18% of group revenue.
• $4.6 million: FY26 international direct contribution, equivalent to approximately 4% of group direct contribution.
• $122.8 million: Illustrative pro-forma cash and marketable securities, based on September 2026 holdings and proposed sale proceeds.
• $5.3 million: Underlying EBITDA for the September 2026 quarter, down 52% year-on-year.

Mayne Pharma Announces Major International Divestment

On 6 November 2026, Mayne Pharma announced a binding agreement to sell Mayne Pharma International to Evaris Pharma.

The transaction covers its Salisbury manufacturing facility in South Australia, contract development and manufacturing operations, and Australian and international commercial businesses.

The sale represents approximately 0.79 times FY26 international revenue and 12.1 times direct contribution.

These figures suggest Mayne Pharma is securing meaningful consideration for a business contributing relatively little to group segment earnings.

Following completion, Mayne Pharma will retain its US Women's Health, Dermatology and DistributeRx operations.

Agreed supply arrangements will preserve manufacturing access for DORYX MPC and TOLSURA, reducing potential operational disruption associated with exiting Salisbury.

Completion is expected in the third quarter of FY27, subject to Australian Competition and Consumer Commission clearance and customary conditions.

The agreement requires neither buyer financing nor shareholder approval.

What Stands Out: A Stronger Balance Sheet Meets Earnings Pressure

Mayne Pharma held $67.3 million in cash and marketable securities at 30 September 2026.

Adding the proposed $55.5 million proceeds produces an illustrative $122.8 million position, although actual completion-date liquidity will depend on intervening cash flows and transaction adjustments.

The financial flexibility is significant given recent operating performance.

September-quarter revenue declined 2% to $95.7 million, while underlying EBITDA fell from $11 million to $5.3 million.

Adjusted operating cash flow from continuing operations was negative $2.1 million before additional royalty and legal payments.

Meanwhile, FY26 underlying EBITDA declined 27% to $34.2 million.

These results indicate that improving liquidity alone will not resolve earnings pressure.

The divestment could simplify capital allocation, but its ultimate financial benefit depends on retained corporate costs, separation expenses and the profitability of remaining operations.

What Mayne Pharma Is Doing Now

Mayne Pharma is expanding its US women's health portfolio and scaling its DistributeRx prescription distribution platform.

During the September quarter, BIJUVA prescriptions increased 25%, IMVEXXY prescriptions rose 13%, and NEXTSTELLIS demand cycles grew 27%.

DistributeRx processed approximately 84,000 prescriptions, representing 120% year-on-year growth.

Its expanded Lexington fulfilment facility is expected to commence operations in early 2027, creating additional distribution capacity.

Patent settlements with Sun Pharma and Teva also established agreed IMVEXXY generic entry dates in 2032, subject to applicable conditions.

However, dermatology competition, commercial investment costs and continuing Cosette-related damages litigation remain important considerations.

Insight: Is the Restructuring Enough to Unlock Value?

We think Mayne Pharma's $55.5 million divestment is strategically positive because it monetises an operation generating only $4.6 million in annual direct contribution while strengthening financial flexibility. However, direct contribution is not the same as EBITDA or free cash flow, making the transaction multiple an imperfect valuation measure. The remaining US businesses offer prescription growth, established pharmaceutical products and distribution infrastructure, but declining underlying earnings demonstrate that commercial momentum has not translated into stronger profitability. Our assessment would improve with evidence of sustainable operating cash generation and recovering margins.

What Happens Next?

The immediate milestone is regulatory clearance and completion of the international divestment during the third quarter of FY27.

Beyond that, the market will be watching DistributeRx's Lexington expansion, women's health prescription growth and the financial impact of continued dermatology competition.

A recovery in underlying EBITDA and operating cash flow would strengthen the case for Mayne Pharma's US-focused strategy.

The $55.5 million sale provides a more flexible financial foundation. The decisive test is whether the remaining pharmaceutical business can turn that advantage into stronger, sustainable earnings.